Company Interview / Big year ahead with Phase 3 progress & FDA fast track momentum

Marc Voigt CEO of biotech Immutep (ASX: IMM) states recent clinical trial results for cancer drug, particularly in the first-line treatment of head and neck cancer, show promise. Voigt also highlights ongoing phase three trials in non-small cell lung cancer as a key focus for Immutep, positioning it as a first for an Australian company in this large cancer indication.

Voigt addresses the operational and regulatory complexities, explaining that partnerships with pharmaceutical companies like Merck and international research institutes are vital for managing multifaceted trial obligations and regulatory interactions.

Financially, Voigt reports Immutep holds approximately $130 million in cash, supporting operations until the end of 2026. Funding prioritises major trials, particularly in lung cancer, while leveraging non-dilutive sources such as R&D incentives and government grants. Major upcoming milestones include new trial data releases at significant oncology conferences and continued operational updates throughout 2025.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD